Aurobindo Pharma Limited announced that its wholly owned subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus® in the US market. This launch represents the first product from Aurobindo’s inhalation pipeline to be commercialized in the US, underscoring the company’s strategic focus on complex and differentiated respiratory products. The generic Advair Diskus® is available in 100/50 mcg and 250/50 mcg strengths and is indicated for asthma and COPD treatment.
New Generic Product Launch in US Market
Aurobindo Pharma Limited has announced a significant development in its US market presence. Its wholly owned subsidiary, Lannett Company LLC, has successfully launched the generic equivalent of Advair Diskus®. This important product, which is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD), is now available in the US market in two key strengths: 100/50 mcg and 250/50 mcg.
Strategic Milestone for Inhalation Pipeline
This launch is a pivotal moment for Aurobindo Pharma, marking the first product from its inhalation pipeline to be commercialized within the United States. The company views this as a reflection of its ongoing commitment and strategic focus on expanding its portfolio with complex and differentiated inhalation products. The Advair Diskus® generic is a combination therapy that addresses significant respiratory health needs.
About Aurobindo Pharma Limited
Aurobindo Pharma Limited is a globally integrated pharmaceutical company headquartered in Hyderabad, India. The company is involved in the development, manufacturing, and commercialization of a wide array of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients. Aurobindo’s products are distributed in over 150 countries. The company operates more than 30 manufacturing and packaging facilities that hold approvals from leading regulatory agencies worldwide, including the USFDA, UK MHRA, and Japan PMDA. Its diverse product portfolio spans across seven major therapeutic areas, supported by a robust research and development infrastructure.
Source: BSE
